Please provide your email address to receive an email when new articles are posted on . The humoral response to BP180 and BP230 antigens is weakened in certain patients with gliptin-associated bullous ...

(HealthDay News) — Gliptin treatment is associated with increased acute pancreatitis risk, according to research published online Sept. 22 in Diabetes Care. Ivan Tkac, M.D., Ph.D., from Pasteur ...

New diabetes drug lowers cost by 80% With the launch of teneligliptin molecule, the popular gliptin category has witnessed a price erosion of over 80% in the last six months, bringing down the cost ...

Data from two trials designed to test the cardiovascular safety of the dipeptidyl peptidase 4 inhibitors saxagliptin and alogliptin, respectively, indicate that these drugs do not increase the ...

India's Zydus Cadila could be about to shake up the India market for diabetes drugs with its Nov. 20 launch of Tenglyn (teneligliptin) for controlling hypoglycemia associated with the Type 2 version ...

MUMBAI: In a move that could potentially disrupt the anti-diabetes drug market in India and lead to a price war, Ahmedabad based Zydus Cadila on Friday said it launched its brand Tenglyn, pricing it ...

The research included data from over 18,000 patients with type 2 diabetes treated with gliptin medications. The incidences of pancreatitis were compared with a similar number of patients treated with ...

The new trials were conducted to fulfill the 2008 US Food and Drug Administration (FDA) requirement for cardiovascular safety studies in all diabetes drugs — prompted at the time by widely publicized ...

The price of diabetes drugs have halved in the past nine months, bringing relief to around millions of diabetics in India. According to a conservative estimate, a diabetic on gliptin treatment saves ...

Ahmedabad-based Zydus Cadila is launching an anti-diabetic drug teneligliptin at an aggressive price of Rs 7 per day, almost 1/6th the price at which gliptins were initially launched in India.

A completely new drug in the ‘gliptin’ family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%. With the launch of the teneligliptin molecule, the popular ...